Nektar Therapeutics Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31)
Nektar Therapeutics (NKTR) had Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) of $213.31 million as of 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesFairValueDisclosure · last filed 2013-05-09
- 2013-03-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $213.31M.
- 2012-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $252.76M.
- 2012-09-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $318.96M.
- 2011-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $399.62M.
| Period end | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $213.31M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $252.76M 10-Q · filed 2013-05-09 |
| 2012-09-30 | $318.96M 10-Q · filed 2012-11-09 |
| 2011-12-31 | $399.62M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |